However, the recently announced interim results of the SKYSCRAPER–01 phase 3 trial that evaluated tiragolumab plus atezolizumab as 1st–line treatment for patients with PD–L1–high metastatic PD–L1 NSCLC did not meet its primary endpoint. Here, CD274 is linked to non-small cell lung carcinoma.